What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein found in human gastric juice. First isolated and characterized by researchers at the University of Zagreb, BPC-157 has been the subject of extensive preclinical investigation since the early 1990s.[11]
The peptide demonstrates notable stability in human gastric juice — a property that distinguishes it from many endogenous peptides that rapidly degrade under acidic conditions. This stability has made it a compelling subject for gastrointestinal research, where it has been studied in models of ulcers, fistulas, inflammatory bowel conditions, and mucosal lesions.[9]
Beyond GI applications, BPC-157 research has expanded into musculoskeletal tissue repair, neurological research, cardioprotection, and tissue repair across multiple organ systems. Sikiric et al. have published extensively on the peptide’s broad cytoprotective properties, documenting effects across more than a dozen animal models over three decades of research.[12]
BPC-157 is classified as a research compound. It has not been approved by the FDA for any therapeutic indication. All information presented here reflects findings from published preclinical and in-vitro studies.
Mechanism of Action
The precise molecular mechanisms of BPC-157 remain under active investigation. Published research suggests several interrelated pathways:[8]
- Nitric Oxide (NO) System Modulation: BPC-157 appears to interact with the nitric oxide system, influencing blood vessel formation and tissue perfusion. Studies suggest it may counteract the effects of NO synthase inhibitors and NO system disruptions.[15]
- Growth Factor Upregulation: Research indicates BPC-157 may upregulate growth factor expression, including EGF, VEGF, and FGF2, which are central to angiogenesis and tissue repair processes.[8]
- FAK-Paxillin Pathway Activation: In tendon tissue repair models, BPC-157 has been shown to activate the FAK-paxillin signaling pathway, promoting tendon outgrowth, cell survival, and cell migration.[3]
- Dopaminergic System Interaction: CNS research suggests BPC-157 interacts with dopaminergic and serotonergic pathways, which may underlie some of its observed neurological research effects.[4]
- Inflammation Research Pathways: BPC-157 has demonstrated effects on inflammatory mediators, with studies showing modulation of cytokine profiles and effects on oxidative stress markers in various tissue injury models.[16]
Key Research Findings
Gastrointestinal Protection
The gastrointestinal tract represents the most extensively studied area for BPC-157. As a derivative of gastric juice proteins, the peptide demonstrates intrinsic stability in the acidic gastric environment — a property that has driven substantial research interest.[11]
Sikiric et al. (2017) published a comprehensive review examining BPC-157 in the context of gastrointestinal stress responses. The review synthesized data from numerous animal models demonstrating the peptide’s cytoprotective effects against ethanol-induced gastric lesions, NSAID-induced damage, and stress-related mucosal injury.[9]
In models of intestinal fistulas, BPC-157 has shown activity in promoting closure of colocutaneous, gastrocutaneous, esophagocutaneous, and duodenocutaneous fistulas. A 2020 review in Current Pharmaceutical Design consolidated evidence from multiple fistula tissue repair studies.[5]
The interaction between BPC-157 and standard angiogenic growth factors in the GI tract was examined by Seiwerth et al. (2018), who reported that the peptide’s GI research applications may be mediated in part through modulation of EGF, VEGF, and other growth factors central to mucosal repair.[8]
Preclinical research has also examined BPC-157 in inflammatory bowel disease models. Studies in experimental colitis demonstrated reduced mucosal damage scores and attenuated inflammatory cytokine expression, suggesting potential relevance to IBD research.[14]
Hepatoprotective properties have also been investigated, with studies examining BPC-157 effects on liver lesions induced by various agents. Ilic et al. reported cytoprotective activity in hepatic injury models, further supporting the peptide’s broad GI-related protective profile.[13]
Musculoskeletal Research
BPC-157 has been studied across multiple musculoskeletal tissue types including tendons, ligaments, muscle, and bone. Gwyer, Wragg, and Wilson (2019) published a review in Cell and Tissue Research examining the evidence for BPC-157 in accelerating musculoskeletal soft tissue repair, noting the peptide’s effects on fibroblast migration and growth factor modulation.[1]
Original research by Chang et al. (2011) in the Journal of Applied Physiology provided mechanistic evidence for BPC-157’s tendon tissue repair research applications. The study demonstrated that BPC-157 promoted tendon outgrowth, enhanced cell survival under stress conditions, and has been studied for effects on cell migration through activation of the FAK-paxillin signaling pathway.[3]
A 2025 systematic review in HSS Journal evaluated the emerging use of BPC-157 in orthopaedic sports medicine contexts, examining the cumulative evidence from preclinical models relevant to sports injuries.[7]
McGuire et al. (2025) published a narrative review in Current Reviews in Musculoskeletal Medicine examining both the regenerative potential and risk considerations of BPC-157 for musculoskeletal tissue repair applications.[6]
Staresinic et al. (2006) examined the effects of BPC-157 on muscle tissue repair in a rat model with surgically transected quadriceps muscle, reporting accelerated functional recovery and improved muscle tissue repair outcomes compared to controls.[17]
Achilles tendon-to-bone tissue repair was investigated by Cerovecki et al. (2010), who reported that BPC-157 administration promoted superior tissue repair at the tendon-bone junction, with improved biomechanical and histological outcomes.[18]
Neurological Research & Brain-Gut Axis
Research into BPC-157’s central nervous system effects has emerged as a significant area of investigation. Vukojević et al. (2022) published a review in Neural Regeneration Research examining the evidence for BPC-157 interactions with the CNS, including effects on dopaminergic and serotonergic systems.[4]
The brain-gut axis represents a particularly compelling research direction for BPC-157. Sikiric et al. (2016) published a detailed examination of the theoretical and practical implications of BPC-157 within the brain-gut axis framework in Current Neuropharmacology, proposing that many of BPC-157’s systemic effects may be mediated through bidirectional gut-brain signaling.[10]
Studies have also examined BPC-157 in models of traumatic brain injury and peripheral nerve damage. Tudek et al. (2021) reviewed evidence suggesting neuroprotective effects mediated through inflammation research pathways and modulation of neurotrophic factors, highlighting potential relevance to nerve regeneration research.[19]
Additional preclinical work has investigated BPC-157’s effects on dopamine system dysfunction, with studies examining the peptide in models of amphetamine and haloperidol-induced behavioral changes, reporting normalization of dopaminergic activity.[20]
Summary of Research
BPC-157 remains one of the most extensively studied synthetic peptides in preclinical research. Over three decades, published literature has documented the peptide’s activity across multiple biological systems:
- Gastrointestinal: Cytoprotection in ulcer, fistula, and inflammatory bowel disease models, with demonstrated stability in gastric juice.[9][11]
- Musculoskeletal: Accelerated tissue repair in tendon, ligament, muscle, and bone injury models via FAK-paxillin and growth factor pathways.[1][3]
- Tissue Repair: Enhanced tissue repair across skin, muscle, and visceral organs with angiogenic activity.[2][8]
- Neurological Research: CNS interactions through dopaminergic and serotonergic pathways within the brain-gut axis framework.[4][10]
While preclinical evidence is substantial, it is important to note that human clinical trial data remains limited. BPC-157 has not been approved for therapeutic use by any regulatory agency. Ongoing research continues to elucidate the peptide’s mechanism of action and potential translational applications.
Frequently Asked Questions
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids with the sequence GEPPPGKPADDAGLV. It is derived from a protective protein naturally found in human gastric juice. The compound was first isolated and characterized by researchers at the University of Zagreb in Croatia, and has been the subject of preclinical research since the early 1990s.
BPC-157 has been studied in preclinical models across four major domains: gastrointestinal protection (ulcers, fistulas, inflammatory bowel conditions), musculoskeletal research (tendon, ligament, muscle, and bone tissue repair), tissue repair across multiple tissue types, and neurological research via brain-gut axis interactions. Published studies have examined effects on the nitric oxide system, angiogenesis, and various growth factor pathways.
No. BPC-157 has not been approved by the FDA or any regulatory agency for therapeutic use in humans. It is classified as a research compound. All findings discussed in this profile are derived from preclinical (animal model) and in-vitro studies. Products sold by Improved Peptides are intended for research use only and are not intended for human consumption.
Published research suggests BPC-157 may act through multiple interrelated pathways: modulation of the nitric oxide (NO) system affecting blood vessel formation, upregulation of growth factors including EGF, VEGF, and FGF2, activation of the FAK-paxillin signaling pathway in tendon tissue repair, and interaction with central dopaminergic and serotonergic systems. The full mechanism remains under active investigation.
BPC-157 demonstrates remarkable stability in human gastric juice, which is highly acidic (pH 1-3). Most endogenous peptides rapidly degrade under these conditions. This stability, combined with documented cytoprotective activity across multiple organ systems in preclinical models, distinguishes BPC-157 from many other research peptides. Its origin from a naturally occurring gastric protein also makes it a unique subject for translational GI research.
Hundreds of preclinical studies have been published on BPC-157 since the early 1990s, indexed across PubMed and other scientific databases. This research profile cites 22 peer-reviewed publications covering the peptide’s primary research domains. The majority of published research originates from the University of Zagreb research group led by Professor Predrag Sikiric, with additional contributions from independent laboratories worldwide.
About this research overview. This article summarizes published peer-reviewed literature on this compound for research-use-only context. Improved Peptides products are research compounds and are not drugs, supplements, or foods. They are not intended for human or animal consumption. Citations link to the original studies for independent verification.
Citations
BPC-157 is most commonly studied alongside TB-500 in the so-called Wolverine Stack research profile, where the two peptides are examined for complementary tissue-repair pathways.
Researchers comparing BPC-157 to longevity-class compounds also reference the epithalon literature for telomerase-related repair pathways.